Simplify Logo

Full-Time

Associate Scientist

Structural Biology

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Hardware
Biotechnology
Healthcare

Compensation Overview

$100k - $135kAnnually

Senior, Expert

San Carlos, CA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Communications
Requirements
  • MSc. degree with 5+ years of experience or BSc. degree and a minimum of 8 years of experience
  • Experience with protein purification (AKTA) and/or biophysical characterization (Thermal melt, CD, SPR, anSEC).
  • Experience with protein-protein complexes including antibodies/Fabs, molecular glues, PROTACs, etc.
  • Experience with growing and harvesting protein crystals, preparing samples for CryoEM, prior use of structure determination/visualization software (CCP4, Phenix, Coot, PyMOL, Chimera), and/or CryoEM (Relion. CryoSPARC) are highly desirable skills.
  • Demonstrated ability to follow written protocols and document research progress.
  • Excellent written and verbal communication skills.
  • Conscientious team-player interested in a fast-paced biotech environment.
  • Demonstrated willingness to learn and improve processes.
Responsibilities
  • Preparation of protein complexes for structural analysis (Crystallography/CryoEM)
  • Operate laboratory robotics for preparing and inspection of crystallization trials.
  • Communicate experimental design and results to cross-functional teams.
  • Manage and document experiments.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to inhibit the activity of RAS proteins that promote cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses specifically on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

40%

2 year growth

111%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.